159 related articles for article (PubMed ID: 35395548)
1. Dose-dependent effects of Varenicline on tobacco craving and withdrawal in tobacco smokers with and without schizophrenia.
Johnstone S; Sorkhou M; Rabin RA; George TP
Drug Alcohol Depend; 2022 May; 234():109412. PubMed ID: 35395548
[TBL] [Abstract][Full Text] [Related]
2. The Relationship of Varenicline Agonism of α4β2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans.
McCaul ME; Wand GS; Kuwabara H; Dannals RF; Wong D; Xu X
Nicotine Tob Res; 2020 May; 22(6):892-899. PubMed ID: 31096265
[TBL] [Abstract][Full Text] [Related]
3. Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation.
Dunn KE; Marcus TF; Kim C; Schroeder JR; Vandrey R; Umbricht A
Nicotine Tob Res; 2016 May; 18(5):1171-9. PubMed ID: 26476459
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Effects of Varenicline on Craving, Withdrawal, and Affect in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline for Smokeless Tobacco Dependence in India.
Jhanjee S; Jain R; Jain V; Gupta T; Mittal S; Goelz P; Schnoll RA
J Psychoactive Drugs; 2015; 47(4):325-30. PubMed ID: 26317176
[TBL] [Abstract][Full Text] [Related]
5. Anxiety Sensitivity and Distress Tolerance in Smokers: Relations With Tobacco Dependence, Withdrawal, and Quitting Success†.
Schlam TR; Baker TB; Smith SS; Cook JW; Piper ME
Nicotine Tob Res; 2020 Jan; 22(1):58-65. PubMed ID: 31056710
[TBL] [Abstract][Full Text] [Related]
6. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
Shiffman S
Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
[TBL] [Abstract][Full Text] [Related]
7. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
West R; Baker CL; Cappelleri JC; Bushmakin AG
Psychopharmacology (Berl); 2008 Apr; 197(3):371-7. PubMed ID: 18084743
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of varenicline or combination nicotine replacement therapy versus patch monotherapy on candidate mediators of early abstinence in a smoking cessation attempt.
Kim N; McCarthy DE; Piper ME; Baker TB
Addiction; 2021 Apr; 116(4):926-935. PubMed ID: 32888230
[TBL] [Abstract][Full Text] [Related]
9. Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse.
Herrmann ES; Cooper ZD; Bedi G; Ramesh D; Reed SC; Comer SD; Foltin RW; Haney M
Addict Biol; 2019 Jul; 24(4):765-776. PubMed ID: 30378231
[TBL] [Abstract][Full Text] [Related]
10. Effects of varenicline on smoking cue–triggered neural and craving responses.
Franklin T; Wang Z; Suh JJ; Hazan R; Cruz J; Li Y; Goldman M; Detre JA; O'Brien CP; Childress AR
Arch Gen Psychiatry; 2011 May; 68(5):516-26. PubMed ID: 21199958
[TBL] [Abstract][Full Text] [Related]
11. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
[TBL] [Abstract][Full Text] [Related]
12. Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers.
Nakamura M; Oshima A; Ohkura M; Arteaga C; Suwa K
Clin Ther; 2014 Jun; 36(6):918-27. PubMed ID: 24811751
[TBL] [Abstract][Full Text] [Related]
13. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Rollema H; Hurst RS
Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
[TBL] [Abstract][Full Text] [Related]
14. Varenicline: for smoking cessation.
Rao J; Shankar PK
Kathmandu Univ Med J (KUMJ); 2009; 7(26):162-4. PubMed ID: 20071853
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive varenicline treatment for smoking reduction in patients with schizophrenia: A randomized double-blind placebo-controlled trial.
Jeon DW; Shim JC; Kong BG; Moon JJ; Seo YS; Kim SJ; Oh MK; Jung DU
Schizophr Res; 2016 Oct; 176(2-3):206-211. PubMed ID: 27543252
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers.
Ravva P; Gastonguay MR; Faessel HM; Lee TC; Niaura R
Nicotine Tob Res; 2015 Jan; 17(1):106-13. PubMed ID: 25145377
[TBL] [Abstract][Full Text] [Related]
17. Effects on abstinence of nicotine patch treatment before quitting smoking: parallel, two arm, pragmatic randomised trial.
Preloading Investigators
BMJ; 2018 Jun; 361():k2164. PubMed ID: 29899061
[TBL] [Abstract][Full Text] [Related]
18. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
[TBL] [Abstract][Full Text] [Related]
19. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
[TBL] [Abstract][Full Text] [Related]
20. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
